Why Did Bill Ackman Buy Uber Stock?
In February, Pershing Square manager Bill Ackman revealed that his…
Sell
45
ATAI Quote, Financials, Valuation and Earnings
Last price:
$1.53
Seasonality move
:
-11.75%
Day range:
$1.48 - $1.56
52-week range:
$1.03 - $2.57
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
737.67x
P/B ratio:
2.61x
Volume:
1.1M
Avg. volume:
1.7M
1-year change:
-18.18%
Market cap:
$303.4M
Revenue:
$308K
EPS (TTM):
-$0.93
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ATAI
ATAI Life Sciences NV
|
-- | -$0.18 | 1288.89% | -5.88% | $8.00 |
|
AFMD
Affimed NV
|
$1.3M | -$0.57 | 675.99% | -58.88% | $12.97 |
|
BNTX
BioNTech SE
|
$184.2M | -$2.67 | 8.88% | -24.72% | $140.40 |
|
FMS
Fresenius Medical Care AG
|
$5.3B | $0.44 | 13.89% | 59.76% | $27.56 |
|
IFRX
InflaRx NV
|
$37.4K | -$0.19 | -5.26% | -0.05% | $9.24 |
|
MNMD
Mind Medicine
|
-- | -$0.37 | -- | -67.92% | $24.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ATAI
ATAI Life Sciences NV
|
$1.53 | $8.00 | $303.4M | -- | $0.00 | 0% | 737.67x |
|
AFMD
Affimed NV
|
$0.89 | $12.97 | $14.6M | -- | $0.00 | 0% | 14.41x |
|
BNTX
BioNTech SE
|
$120.54 | $140.40 | $29B | 191.55x | $0.00 | 0% | 9.74x |
|
FMS
Fresenius Medical Care AG
|
$24.17 | $27.56 | $14.2B | 24.20x | $0.64 | 2.66% | 0.68x |
|
IFRX
InflaRx NV
|
$1.32 | $9.24 | $88.6M | -- | $0.00 | 0% | 428.00x |
|
MNMD
Mind Medicine
|
$6.43 | $24.50 | $484.6M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ATAI
ATAI Life Sciences NV
|
16.81% | 2.949 | 10.51% | 2.55x |
|
AFMD
Affimed NV
|
31.93% | 1.456 | 16.35% | 1.76x |
|
BNTX
BioNTech SE
|
1.29% | 1.937 | 0.97% | 7.26x |
|
FMS
Fresenius Medical Care AG
|
31.93% | 0.260 | 48.99% | 0.95x |
|
IFRX
InflaRx NV
|
-- | 4.794 | -- | 3.85x |
|
MNMD
Mind Medicine
|
-- | 0.826 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ATAI
ATAI Life Sciences NV
|
-- | -$30.4M | -74.54% | -83.02% | 764640% | -$24.4M |
|
AFMD
Affimed NV
|
-- | -$15.7M | -127.62% | -158.94% | -9594.22% | -$13.2M |
|
BNTX
BioNTech SE
|
$1B | $924.4M | -3.35% | -3.39% | 25.13% | -$605.5M |
|
FMS
Fresenius Medical Care AG
|
$1.4B | $466.2M | 2.41% | 3.56% | 5.53% | $1.1B |
|
IFRX
InflaRx NV
|
-$3M | -$10.4M | -56.78% | -56.78% | 1207051.66% | -$12.3M |
|
MNMD
Mind Medicine
|
-- | -$32.5M | -- | -- | -- | -$25.4M |
ATAI Life Sciences NV vs. Competitors
-
Which has Higher Returns ATAI or AFMD?
Affimed NV has a net margin of -65715% compared to ATAI Life Sciences NV's net margin of -9767.12%. ATAI Life Sciences NV's return on equity of -83.02% beat Affimed NV's return on equity of -158.94%.
Company Gross Margin Earnings Per Share Invested Capital ATAIATAI Life Sciences NV-- -$0.24 $140.1M AFMDAffimed NV-- -$1.03 $28.2M -
What do Analysts Say About ATAI or AFMD?
ATAI Life Sciences NV has a consensus price target of $8.00, signalling upside risk potential of 422.88%. On the other hand Affimed NV has an analysts' consensus of $12.97 which suggests that it could grow by 1357.71%. Given that Affimed NV has higher upside potential than ATAI Life Sciences NV, analysts believe Affimed NV is more attractive than ATAI Life Sciences NV.
Company Buy Ratings Hold Ratings Sell Ratings ATAIATAI Life Sciences NV4 0 0 AFMDAffimed NV4 0 0 -
Is ATAI or AFMD More Risky?
ATAI Life Sciences NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Affimed NV has a beta of 2.280, suggesting its more volatile than the S&P 500 by 127.999%.
-
Which is a Better Dividend Stock ATAI or AFMD?
ATAI Life Sciences NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Affimed NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ATAI Life Sciences NV pays -- of its earnings as a dividend. Affimed NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATAI or AFMD?
ATAI Life Sciences NV quarterly revenues are -$5K, which are smaller than Affimed NV quarterly revenues of $170.5K. ATAI Life Sciences NV's net income of -$39M is lower than Affimed NV's net income of -$16.7M. Notably, ATAI Life Sciences NV's price-to-earnings ratio is -- while Affimed NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ATAI Life Sciences NV is 737.67x versus 14.41x for Affimed NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATAIATAI Life Sciences NV737.67x -- -$5K -$39M AFMDAffimed NV14.41x -- $170.5K -$16.7M
-
Which has Higher Returns ATAI or BNTX?
BioNTech SE has a net margin of -65715% compared to ATAI Life Sciences NV's net margin of 21.81%. ATAI Life Sciences NV's return on equity of -83.02% beat BioNTech SE's return on equity of -3.39%.
Company Gross Margin Earnings Per Share Invested Capital ATAIATAI Life Sciences NV-- -$0.24 $140.1M BNTXBioNTech SE79.54% $1.15 $20.5B -
What do Analysts Say About ATAI or BNTX?
ATAI Life Sciences NV has a consensus price target of $8.00, signalling upside risk potential of 422.88%. On the other hand BioNTech SE has an analysts' consensus of $140.40 which suggests that it could grow by 16.47%. Given that ATAI Life Sciences NV has higher upside potential than BioNTech SE, analysts believe ATAI Life Sciences NV is more attractive than BioNTech SE.
Company Buy Ratings Hold Ratings Sell Ratings ATAIATAI Life Sciences NV4 0 0 BNTXBioNTech SE13 5 0 -
Is ATAI or BNTX More Risky?
ATAI Life Sciences NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BioNTech SE has a beta of 1.069, suggesting its more volatile than the S&P 500 by 6.943%.
-
Which is a Better Dividend Stock ATAI or BNTX?
ATAI Life Sciences NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ATAI Life Sciences NV pays -- of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATAI or BNTX?
ATAI Life Sciences NV quarterly revenues are -$5K, which are smaller than BioNTech SE quarterly revenues of $1.3B. ATAI Life Sciences NV's net income of -$39M is lower than BioNTech SE's net income of $276.6M. Notably, ATAI Life Sciences NV's price-to-earnings ratio is -- while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ATAI Life Sciences NV is 737.67x versus 9.74x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATAIATAI Life Sciences NV737.67x -- -$5K -$39M BNTXBioNTech SE9.74x 191.55x $1.3B $276.6M
-
Which has Higher Returns ATAI or FMS?
Fresenius Medical Care AG has a net margin of -65715% compared to ATAI Life Sciences NV's net margin of 1.32%. ATAI Life Sciences NV's return on equity of -83.02% beat Fresenius Medical Care AG's return on equity of 3.56%.
Company Gross Margin Earnings Per Share Invested Capital ATAIATAI Life Sciences NV-- -$0.24 $140.1M FMSFresenius Medical Care AG24.99% $0.12 $23.5B -
What do Analysts Say About ATAI or FMS?
ATAI Life Sciences NV has a consensus price target of $8.00, signalling upside risk potential of 422.88%. On the other hand Fresenius Medical Care AG has an analysts' consensus of $27.56 which suggests that it could grow by 14.03%. Given that ATAI Life Sciences NV has higher upside potential than Fresenius Medical Care AG, analysts believe ATAI Life Sciences NV is more attractive than Fresenius Medical Care AG.
Company Buy Ratings Hold Ratings Sell Ratings ATAIATAI Life Sciences NV4 0 0 FMSFresenius Medical Care AG1 3 1 -
Is ATAI or FMS More Risky?
ATAI Life Sciences NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Fresenius Medical Care AG has a beta of 0.935, suggesting its less volatile than the S&P 500 by 6.546%.
-
Which is a Better Dividend Stock ATAI or FMS?
ATAI Life Sciences NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fresenius Medical Care AG offers a yield of 2.66% to investors and pays a quarterly dividend of $0.64 per share. ATAI Life Sciences NV pays -- of its earnings as a dividend. Fresenius Medical Care AG pays out 64.91% of its earnings as a dividend. Fresenius Medical Care AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ATAI or FMS?
ATAI Life Sciences NV quarterly revenues are -$5K, which are smaller than Fresenius Medical Care AG quarterly revenues of $5.4B. ATAI Life Sciences NV's net income of -$39M is lower than Fresenius Medical Care AG's net income of $71.3M. Notably, ATAI Life Sciences NV's price-to-earnings ratio is -- while Fresenius Medical Care AG's PE ratio is 24.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ATAI Life Sciences NV is 737.67x versus 0.68x for Fresenius Medical Care AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATAIATAI Life Sciences NV737.67x -- -$5K -$39M FMSFresenius Medical Care AG0.68x 24.20x $5.4B $71.3M
-
Which has Higher Returns ATAI or IFRX?
InflaRx NV has a net margin of -65715% compared to ATAI Life Sciences NV's net margin of -14092.9%. ATAI Life Sciences NV's return on equity of -83.02% beat InflaRx NV's return on equity of -56.78%.
Company Gross Margin Earnings Per Share Invested Capital ATAIATAI Life Sciences NV-- -$0.24 $140.1M IFRXInflaRx NV-5376.61% -$0.09 $63.9M -
What do Analysts Say About ATAI or IFRX?
ATAI Life Sciences NV has a consensus price target of $8.00, signalling upside risk potential of 422.88%. On the other hand InflaRx NV has an analysts' consensus of $9.24 which suggests that it could grow by 599.81%. Given that InflaRx NV has higher upside potential than ATAI Life Sciences NV, analysts believe InflaRx NV is more attractive than ATAI Life Sciences NV.
Company Buy Ratings Hold Ratings Sell Ratings ATAIATAI Life Sciences NV4 0 0 IFRXInflaRx NV4 1 0 -
Is ATAI or IFRX More Risky?
ATAI Life Sciences NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison InflaRx NV has a beta of 2.206, suggesting its more volatile than the S&P 500 by 120.591%.
-
Which is a Better Dividend Stock ATAI or IFRX?
ATAI Life Sciences NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ATAI Life Sciences NV pays -- of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATAI or IFRX?
ATAI Life Sciences NV quarterly revenues are -$5K, which are smaller than InflaRx NV quarterly revenues of -$450. ATAI Life Sciences NV's net income of -$39M is lower than InflaRx NV's net income of -$5.4M. Notably, ATAI Life Sciences NV's price-to-earnings ratio is -- while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ATAI Life Sciences NV is 737.67x versus 428.00x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATAIATAI Life Sciences NV737.67x -- -$5K -$39M IFRXInflaRx NV428.00x -- -$450 -$5.4M
-
Which has Higher Returns ATAI or MNMD?
Mind Medicine has a net margin of -65715% compared to ATAI Life Sciences NV's net margin of --. ATAI Life Sciences NV's return on equity of -83.02% beat Mind Medicine's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ATAIATAI Life Sciences NV-- -$0.24 $140.1M MNMDMind Medicine-- -$0.41 -- -
What do Analysts Say About ATAI or MNMD?
ATAI Life Sciences NV has a consensus price target of $8.00, signalling upside risk potential of 422.88%. On the other hand Mind Medicine has an analysts' consensus of $24.50 which suggests that it could grow by 281.03%. Given that ATAI Life Sciences NV has higher upside potential than Mind Medicine, analysts believe ATAI Life Sciences NV is more attractive than Mind Medicine.
Company Buy Ratings Hold Ratings Sell Ratings ATAIATAI Life Sciences NV4 0 0 MNMDMind Medicine7 0 0 -
Is ATAI or MNMD More Risky?
ATAI Life Sciences NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Mind Medicine has a beta of 2.387, suggesting its more volatile than the S&P 500 by 138.658%.
-
Which is a Better Dividend Stock ATAI or MNMD?
ATAI Life Sciences NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mind Medicine offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ATAI Life Sciences NV pays -- of its earnings as a dividend. Mind Medicine pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATAI or MNMD?
ATAI Life Sciences NV quarterly revenues are -$5K, which are larger than Mind Medicine quarterly revenues of --. ATAI Life Sciences NV's net income of -$39M is lower than Mind Medicine's net income of -$34.7M. Notably, ATAI Life Sciences NV's price-to-earnings ratio is -- while Mind Medicine's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ATAI Life Sciences NV is 737.67x versus -- for Mind Medicine. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATAIATAI Life Sciences NV737.67x -- -$5K -$39M MNMDMind Medicine-- -- -- -$34.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Should You Buy Alibaba Stock Despite the Risks?
Markets rebounded slightly after U.S. President Donald Trump announced a…
Why Is Intel Struggling Against AMD?
Due to its disappointing reports, so-so management, and lack of…
Stock Ideas
Buy
59
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Buy
54
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.6T
P/E Ratio: 36x
Alerts
Sell
48
FI alert for Apr 25
Fiserv [FI] is up 0.62% over the past day.
Buy
66
FARO alert for Apr 25
Faro Technologies [FARO] is down 1.86% over the past day.
Buy
55
PI alert for Apr 25
Impinj [PI] is up 0.21% over the past day.
